Cancer Chemotherapy and Pharmacology

, Volume 81, Issue 3, pp 443–453 | Cite as

First-line therapy for advanced non-small cell lung cancer with activating EGFR mutation: is combined EGFR-TKIs and chemotherapy a better choice?

Review Article
  • 216 Downloads

Abstract

As the standard first-line treatment for advanced non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutation, EGFR-tyrosine kinase inhibitors (EGFR-TKIs) have significantly improved the median progression-free survival (PFS) up to 18.9 months. However, almost all patients eventually develop acquired resistance to EGFR-TKIs, which limits the first-line PFS. To overcome the resistance and improve overall survival, researchers have tried to identify the resistance mechanisms and develop new treatment strategies, among which a combination of EGFR-TKIs and cytotoxic chemotherapy is one of the hotspots. The data from preclinical and clinical studies on combined EGFR-TKIs and chemotherapy have shown very interesting results. Here, we reviewed the available preclinical and clinical studies on first-line EGFR-TKIs–chemotherapy combination in patients with advanced NSCLC harboring activating EGFR mutation, aiming to provide evidences for more potential choices and shed light on clinical treatment.

Keywords

Activating EGFR mutation NSCLC EGFR-TKIs Cytotoxic chemotherapy First-line treatment 

Notes

Acknowledgements

This work was supported by the National Natural Science Foundation of China (Grant no. 81372334) and Shandong Provincial Natural Science Foundation (Grant no. ZR2017PH076).

Compliance with ethical standards

Conflict of interest

All authors declared that they have no competing interests.

Ethical approval

This article does not contain any studies with human participants performed by any of the authors.

References

  1. 1.
    American Cancer Society (2015) Global cancer facts and figures, 3rd edn. American Cancer Society, AtlantaGoogle Scholar
  2. 2.
    Woodburn JR (1999) The epidermal growth factor receptor and its inhibition in cancer therapy. Pharmacol Therapeutics 82(2–3):241–250CrossRefGoogle Scholar
  3. 3.
    Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, Tsurutani J, Seto T, Satouchi M, Tada H, Hirashima T, Asami K, Katakami N, Takada M, Yoshioka H, Shibata K, Kudoh S, Shimizu E, Saito H, Toyooka S, Nakagawa K, Fukuoka M (2010) Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 11(2):121–128.  https://doi.org/10.1016/s1470-2045(09)70364-x CrossRefPubMedGoogle Scholar
  4. 4.
    Wu YL, Zhou C, Liam CK, Wu G, Liu X, Zhong Z, Lu S, Cheng Y, Han B, Chen L, Huang C, Qin S, Zhu Y, Pan H, Liang H, Li E, Jiang G, How SH, Fernando MC, Zhang Y, Xia F, Zuo Y (2015) First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study. Ann oncol 26(9):1883–1889.  https://doi.org/10.1093/annonc/mdv270 CrossRefPubMedGoogle Scholar
  5. 5.
    Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, Palmero R, Garcia-Gomez R, Pallares C, Sanchez JM, Porta R, Cobo M, Garrido P, Longo F, Moran T, Insa A, De Marinis F, Corre R, Bover I, Illiano A, Dansin E, de Castro J, Milella M, Reguart N, Altavilla G, Jimenez U, Provencio M, Moreno MA, Terrasa J, Muñoz-Langa J, Valdivia J, Isla D, Domine M, Molinier O, Mazieres J, Baize N, Garcia-Campelo R, Robinet G, Rodriguez-Abreu D, Lopez-Vivanco G, Gebbia V, Ferrera-Delgado L, Bombaron P, Bernabe R, Bearz A, Artal A, Cortesi E, Rolfo C, Sanchez-Ronco M, Drozdowskyj A, Queralt C, de Aguirre I, Ramirez JL, Sanchez JJ, Molina MA, Taron M, Paz-Ares L (2012) Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 13(3):239–246.  https://doi.org/10.1016/s1470-2045(11)70393-x CrossRefPubMedGoogle Scholar
  6. 6.
    Wu Y-L, Zhou C, Hu C-P, Feng J, Lu S, Huang Y, Li W, Hou M, Shi JH, Lee KY, Xu C-R, Massey D, Kim M, Shi Y, Geater SL (2014) Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. Lancet Oncol 15(2):213–222.  https://doi.org/10.1016/s1470-2045(13)70604-1 CrossRefPubMedGoogle Scholar
  7. 7.
    Mok T, Wu Y, Thongprasert S, Yang C, Chu D, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y, Nishiwaki Y, Ohe Y, Yang J, Chewaskulyong B, Jiang H, Duffield E, Watkins C, Armour A, Fukuoka M (2009) Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361(10):947–957CrossRefPubMedGoogle Scholar
  8. 8.
    Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I, Fujita Y, Okinaga S, Hirano H, Yoshimori K, Harada T, Ogura T, Ando M, Miyazawa H, Tanaka T, Saijo Y, Hagiwara K, Morita S, Nukiwa T (2010) Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 362(25):2380–2388CrossRefPubMedGoogle Scholar
  9. 9.
    Sequist L, Yang J, Yamamoto N, O’Byrne K, Hirsh V, Mok T, Geater S, Orlov S, Tsai C, Boyer M, Su W, Bennouna J, Kato T, Gorbunova V, Lee K, Shah R, Massey D, Zazulina V, Shahidi M, Schuler M (2013) Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol 31(27):3327–3334CrossRefPubMedGoogle Scholar
  10. 10.
    Zhou C, Wu Y-L, Chen G, Feng J, Liu X-Q, Wang C, Zhang S, Wang J, Zhou S, Ren S, Lu S, Zhang L, Hu C, Hu C, Luo Y, Chen L, Ye M, Huang J, Zhi X, Zhang Y, Xiu Q, Ma J, Zhang L, You C (2011) Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 12(8):735–742.  https://doi.org/10.1016/s1470-2045(11)70184-x CrossRefPubMedGoogle Scholar
  11. 11.
    Wu Y-L, Cheng Y, Zhou X, Lee KH, Nakagawa K, Niho S, Tsuji F, Linke R, Rosell R, Corral J, Migliorino MR, Pluzanski A, Sbar EI, Wang T, White JL, Nadanaciva S, Sandin R, Mok TS (2017) Dacomitinib versus gefitinib as first-line treatment for patients with EGFR -mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial. Lancet Oncol 18(11):1454–1466.  https://doi.org/10.1016/s1470-2045(17)30608-3 CrossRefPubMedGoogle Scholar
  12. 12.
    Soria JC, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH, Dechaphunkul A, Imamura F, Nogami N, Kurata T, Okamoto I, Zhou C, Cho BC, Cheng Y, Cho EK, Voon PJ, Planchard D, Su WC, Gray JE, Lee SM, Hodge R, Marotti M, Rukazenkov Y, Ramalingam SS, Investigators F (2017) Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. N Engl J Med.  https://doi.org/10.1056/NEJMoa1713137 PubMedGoogle Scholar
  13. 13.
    National Comprehensive Cancer Network, Nation Comprehensive Cancer Network clinical practice guidelines in oncology: non-small cell lung cancer, Version 1.2018. https://www.nccn.org/professionals/physician_gls/f_guidelines.asp. Accessed 17 Nov 2017
  14. 14.
    Hanna N, Johnson D, Temin S, Masters G (2017) Systemic Therapy for stage IV non-small-cell lung cancer: american society of clinical oncology clinical practice guideline update summary. J Oncol Pract 13(12):832–837.  https://doi.org/10.1200/jop.2017.026716 CrossRefPubMedGoogle Scholar
  15. 15.
    Kobayashi S, Boggon TJ, Dayaram T, Janne PA, Kocher O, Meyerson M, Johnson BE, Eck MJ, Tenen DG, Halmos B (2005) EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 352(8):786–792.  https://doi.org/10.1056/NEJMoa044238 CrossRefPubMedGoogle Scholar
  16. 16.
    Pao W, Miller VA, Politi KA, Riely GJ, Somwar R, Zakowski MF, Kris MG, Varmus H (2005) Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2(3):e73.  https://doi.org/10.1371/journal.pmed.0020073 CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Bean J, Brennan C, Shih JY, Riely G, Viale A, Wang L, Chitale D, Motoi N, Szoke J, Broderick S, Balak M, Chang WC, Yu CJ, Gazdar A, Pass H, Rusch V, Gerald W, Huang SF, Yang PC, Miller V, Ladanyi M, Yang CH, Pao W (2007) MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci USA 104 (52):20932–20937.  https://doi.org/10.1073/pnas.0710370104 CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, Lindeman N, Gale CM, Zhao X, Christensen J, Kosaka T, Holmes AJ, Rogers AM, Cappuzzo F, Mok T, Lee C, Johnson BE, Cantley LC, Janne PA (2007) MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316(5827):1039–1043.  https://doi.org/10.1126/science.1141478 CrossRefPubMedGoogle Scholar
  19. 19.
    Yano S, Yamada T, Takeuchi S, Tachibana K, Minami Y, Yatabe Y, Mitsudomi T, Tanaka H, Kimura T, Kudoh S, Nokihara H, Ohe Y, Yokota J, Uramoto H, Yasumoto K, Kiura K, Higashiyama M, Oda M, Saito H, Yoshida J, Kondoh K, Noguchi M (2011) Hepatocyte growth factor expression in EGFR mutant lung cancer with intrinsic and acquired resistance to tyrosine kinase inhibitors in a Japanese cohort. J Thorac Oncol 6(12):2011–2017.  https://doi.org/10.1097/JTO.0b013e31823ab0dd CrossRefPubMedGoogle Scholar
  20. 20.
    Sequist LV, Waltman BA, Dias-Santagata D, Digumarthy S, Turke AB, Fidias P, Bergethon K, Shaw AT, Gettinger S, Cosper AK, Akhavanfard S, Heist RS, Temel J, Christensen JG, Wain JC, Lynch TJ, Vernovsky K, Mark EJ, Lanuti M, Iafrate AJ, Mino-Kenudson M, Engelman JA (2011) Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med 3(75):75ra26.  https://doi.org/10.1126/scitranslmed.3002003 CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Zhang Z, Lee JC, Lin L, Olivas V, Au V, LaFramboise T, Abdel-Rahman M, Wang X, Levine AD, Rho JK, Choi YJ, Choi CM, Kim SW, Jang SJ, Park YS, Kim WS, Lee DH, Lee JS, Miller VA, Arcila M, Ladanyi M, Moonsamy P, Sawyers C, Boggon TJ, Ma PC, Costa C, Taron M, Rosell R, Halmos B, Bivona TG (2012) Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer. Nat Genet 44(8):852–860.  https://doi.org/10.1038/ng.2330 CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Yu HA, Arcila ME, Rekhtman N, Sima CS, Zakowski MF, Pao W, Kris MG, Miller VA, Ladanyi M, Riely GJ (2013) Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin Cancer Res 19(8):2240–2247.  https://doi.org/10.1158/1078-0432.ccr-12-2246 CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Thress KS, Paweletz CP, Felip E, Cho BC, Stetson D, Dougherty B, Lai Z, Markovets A, Vivancos A, Kuang Y, Ercan D, Matthews SE, Cantarini M, Barrett JC, Janne PA, Oxnard GR (2015) Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M. Nat Med 21(6):560–562.  https://doi.org/10.1038/nm.3854 CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Janne PA, Yang JC, Kim DW, Planchard D, Ohe Y, Ramalingam SS, Ahn MJ, Kim SW, Su WC, Horn L, Haggstrom D, Felip E, Kim JH, Frewer P, Cantarini M, Brown KH, Dickinson PA, Ghiorghiu S, Ranson M (2015) AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. N Engl J Med 372(18):1689–1699.  https://doi.org/10.1056/NEJMoa1411817 CrossRefPubMedGoogle Scholar
  25. 25.
    Goss G, Tsai C-M, Shepherd FA, Bazhenova L, Lee JS, Chang G-C, Crino L, Satouchi M, Chu Q, Hida T, Han J-Y, Juan O, Dunphy F, Nishio M, Kang J-H, Majem M, Mann H, Cantarini M, Ghiorghiu S, Mitsudomi T (2016) Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncol 17(12):1643–1652.  https://doi.org/10.1016/s1470-2045(16)30508-3 CrossRefPubMedGoogle Scholar
  26. 26.
    Laporte S, Squifflet P, Baroux N, Fossella F, Georgoulias V, Pujol JL, Douillard JY, Kudoh S, Pignon JP, Quinaux E, Buyse M (2013) Prediction of survival benefits from progression-free survival benefits in advanced non-small-cell lung cancer: evidence from a meta-analysis of 2334 patients from 5 randomised trials. BMJ Open.  https://doi.org/10.1136/bmjopen-2012-001802 PubMedPubMedCentralGoogle Scholar
  27. 27.
    Sebastian S, Settleman J, Reshkin SJ, Azzariti A, Bellizzi A, Paradiso A (2006) The complexity of targeting EGFR signalling in cancer: from expression to turnover. Biochim Biophys Acta 1766(1):120–139.  https://doi.org/10.1016/j.bbcan.2006.06.001 PubMedGoogle Scholar
  28. 28.
    Blume-Jensen P, Hunter T (2001) Oncogenic kinase signalling. Nature 411(6835):355–365CrossRefPubMedGoogle Scholar
  29. 29.
    Lemmon MA, Schlessinger J (2010) Cell signaling by receptor tyrosine kinases. Cell 141(7):1117–1134.  https://doi.org/10.1016/j.cell.2010.06.011 CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Kumar A, Petri ET, Halmos B, Boggon TJ (2008) Structure and clinical relevance of the epidermal growth factor receptor in human cancer. J Clin Oncol 26(10):1742–1751.  https://doi.org/10.1200/JCO.2007.12.1178 CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Malhotra V, Perry MC (2003) Classical chemotherapy: mechanisms, toxicities and the therapeutic window. Cancer Biol Therapy 2(4 Suppl 1):S2–S4Google Scholar
  32. 32.
    Cheng H, An SJ, Zhang XC, Dong S, Zhang YF, Chen ZH, Chen HJ, Guo AL, Lin QX, Wu YL (2011) In vitro sequence-dependent synergism between paclitaxel and gefitinib in human lung cancer cell lines. Cancer Chemother Pharmacol 67(3):637–646.  https://doi.org/10.1007/s00280-010-1347-4 CrossRefPubMedGoogle Scholar
  33. 33.
    Cheng H, An SJ, Dong S, Zhang YF, Zhang XC, Chen ZH, Jian S, Wu YL (2011) Molecular mechanism of the schedule-dependent synergistic interaction in EGFR-mutant non-small cell lung cancer cell lines treated with paclitaxel and gefitinib. J Hematol Oncol 4:5.  https://doi.org/10.1186/1756-8722-4-5 CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Van Schaeybroeck S, Kyula J, Kelly DM, Karaiskou-McCaul A, Stokesberry SA, Van Cutsem E, Longley DB, Johnston PG (2006) Chemotherapy-induced epidermal growth factor receptor activation determines response to combined gefitinib/chemotherapy treatment in non-small cell lung cancer cells. Mol Cancer Therapeutics 5(5):1154–1165.  https://doi.org/10.1158/1535-7163.MCT-05-0446 CrossRefGoogle Scholar
  35. 35.
    Wu M, Yuan Y, Pan YY, Zhang Y (2014) Antitumor activity of combination treatment with gefitinib and docetaxel in EGFR-TKI-sensitive, primary resistant and acquired resistant human non-small cell lung cancer cells. Mol Med Rep 9(6):2417–2422.  https://doi.org/10.3892/mmr.2014.2082 CrossRefPubMedGoogle Scholar
  36. 36.
    Vempati P, Popel AS, Mac Gabhann F (2014) Extracellular regulation of VEGF: isoforms, proteolysis, and vascular patterning. Cytokine Growth Factor Rev 25(1):1–19.  https://doi.org/10.1016/j.cytogfr.2013.11.002 CrossRefPubMedGoogle Scholar
  37. 37.
    Tsai CM, Chiu CH, Chang KT, Chen JT, Lai CL, Chen YM, Hsiao SY (2012) Gefitinib enhances cytotoxicities of antimicrotubule agents in non-small-cell lung cancer cells exhibiting no sensitizing epidermal growth factor receptor mutation. J Thorac Oncol 7(8):1218–1227.  https://doi.org/10.1097/JTO.0b013e318258cf17 CrossRefPubMedGoogle Scholar
  38. 38.
    Goldman ID, Zhao R (2002) Molecular, biochemical, and cellular pharmacology of pemetrexed. Semin Oncol 29(6 Suppl 18):3–17.  https://doi.org/10.1053/sonc.2002.37461 CrossRefPubMedGoogle Scholar
  39. 39.
    Calvert AH (2004) Biochemical pharmacology of pemetrexed. Oncology (Williston Park NY) 18(13 Suppl 8):13–17Google Scholar
  40. 40.
    Sigmond J, Backus HHJ, Wouters D, Temmink OH, Jansen G, Peters GJ (2003) Induction of resistance to the multitargeted antifolate Pemetrexed (ALIMTA) in WiDr human colon cancer cells is associated with thymidylate synthase overexpression. Biochem Pharmacol 66(3):431–438.  https://doi.org/10.1016/s0006-2952(03)00287-9 CrossRefPubMedGoogle Scholar
  41. 41.
    Giovannetti E, Lemos C, Tekle C, Smid K, Nannizzi S, Rodriguez JA, Ricciardi S, Danesi R, Giaccone G, Peters GJ (2008) Molecular mechanisms underlying the synergistic interaction of erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor, with the multitargeted antifolate pemetrexed in non-small-cell lung cancer cells. Mol Pharmacol 73(4):1290–1300.  https://doi.org/10.1124/mol.107.042382 CrossRefPubMedGoogle Scholar
  42. 42.
    Li T, Ling YH, Goldman ID, Perez-Soler R (2007) Schedule-dependent cytotoxic synergism of pemetrexed and erlotinib in human non-small cell lung cancer cells. Clin Cancer Res 13(11):3413–3422.  https://doi.org/10.1158/1078-0432.CCR-06-2923 CrossRefPubMedGoogle Scholar
  43. 43.
    La Monica S, Madeddu D, Tiseo M, Vivo V, Galetti M, Cretella D, Bonelli M, Fumarola C, Cavazzoni A, Falco A, Gervasi A, Lagrasta CA, Naldi N, Barocelli E, Ardizzoni A, Quaini F, Petronini PG, Alfieri R (2016) Combination of gefitinib and pemetrexed prevents the acquisition of TKI resistance in NSCLC cell lines carrying EGFR-activating mutation. J Thorac Oncol 11(7):1051–1063.  https://doi.org/10.1016/j.jtho.2016.03.006 CrossRefPubMedGoogle Scholar
  44. 44.
    Tsai C-M, Chen J-T, Chiu C-H, Lai C-L, Hsiao S-Y, Chang K-T (2013) Combined epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor and chemotherapy in non-small-cell lung cancer: chemo-refractoriness of cells harboring sensitizing-EGFR mutations in the presence of gefitinib. Lung Cancer 82(2):305–312.  https://doi.org/10.1016/j.lungcan.2013.08.028 CrossRefPubMedGoogle Scholar
  45. 45.
    Okabe T, Okamoto I, Tsukioka S, Uchida J, Iwasa T, Yoshida T, Hatashita E, Yamada Y, Satoh T, Tamura K, Fukuoka M, Nakagawa K (2008) Synergistic antitumor effect of S-1 and the epidermal growth factor receptor inhibitor gefitinib in non-small cell lung cancer cell lines: role of gefitinib-induced down-regulation of thymidylate synthase. Mol Cancer Therapeutics 7(3):599–606.  https://doi.org/10.1158/1535-7163.MCT-07-0567 CrossRefGoogle Scholar
  46. 46.
    Johnstone TC, Suntharalingam K, Lippard SJ (2016) The next generation of platinum drugs: targeted Pt(II) agents, nanoparticle delivery, and Pt(IV) prodrugs. Chem Rev 116(5):3436–3486.  https://doi.org/10.1021/acs.chemrev.5b00597 CrossRefPubMedPubMedCentralGoogle Scholar
  47. 47.
    Jamieson ER, Lippard SJ (1999) Structure, recognition, and processing of cisplatin-DNA adducts. Chem Rev 99(9):2467–2498CrossRefPubMedGoogle Scholar
  48. 48.
    Liu JT, Li WC, Gao S, Wang F, Li XQ, Yu HQ, Fan LL, Wei W, Wang H, Sun GP (2015) Autophagy inhibition overcomes the antagonistic effect between gefitinib and cisplatin in epidermal growth factor receptor mutant non–small-cell lung cancer cells. Clin Lung Cancer 16(5):e55–e66.  https://doi.org/10.1016/j.cllc.2015.03.006 CrossRefPubMedGoogle Scholar
  49. 49.
    Tsai C, Chen J, Stewart D, Chiu C, Lai C, Hsiao S, Chen Y, Chang K (2011) Antagonism between gefitinib and cisplatin in non-small cell lung cancer cells: why randomized trials failed? J Thorac Oncol 6(3):559–568CrossRefPubMedGoogle Scholar
  50. 50.
    Hanna N, Johnson D, Temin S, Brahmer SB Jr, Ellis PM, Giaccone G, Hesketh PJ, Jaiyesimi I, Leighl NB, Riely GJ, Schiller JH, Schneider BJ, Smith TJ, Tashbar J, Biermann WA, Masters G (2017) Systemic therapy for stage IV non–small-cell lung cancer: american society of clinical oncology clinical practice guideline update. J Clin Oncol.  https://doi.org/10.1200/jco.2017.74.6065 PubMedCentralGoogle Scholar
  51. 51.
    Novello S, Barlesi F, Califano R, Cufer T, Ekman S, Levra MG, Kerr K, Popat S, Reck M, Senan S, Simo GV, Vansteenkiste J, Peters S (2016) Metastatic non-small-cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up†. Ann Oncol 27(suppl_5):v1–v27.  https://doi.org/10.1093/annonc/mdw326 CrossRefPubMedGoogle Scholar
  52. 52.
    Arcila M, Oxnard G, Nafa K, Riely G, Solomon S, Zakowski M, Kris M, Pao W, Miller V, Ladanyi M (2011) Rebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of the T790M mutation using a locked nucleic acid-based assay. Clin Cancer Res 17(5):1169–1180CrossRefPubMedPubMedCentralGoogle Scholar
  53. 53.
    Oxnard G, Arcila M, Sima C, Riely G, Chmielecki J, Kris M, Pao W, Ladanyi M, Miller V (2011) Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: distinct natural history of patients with tumors harboring the T790M mutation. Clin Cancer Res 17(6):1616–1622CrossRefPubMedGoogle Scholar
  54. 54.
    Yu H, Arcila M, Rekhtman N, Sima C, Zakowski M, Pao W, Kris M, Miller V, Ladanyi M, Riely G (2013) Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin Cancer Res 19(8):2240–2247CrossRefPubMedPubMedCentralGoogle Scholar
  55. 55.
    Wu S, Liu Y, Tsai M, Chang Y, Yu C, Yang P, Yang J, Wen Y, Shih J (2016) The mechanism of acquired resistance to irreversible EGFR tyrosine kinase inhibitor-afatinib in lung adenocarcinoma patients. Oncotarget 7(11):12404–12413PubMedPubMedCentralGoogle Scholar
  56. 56.
    Higgins B, Kolinsky K, Smith M, Beck G, Rashed M, Adames V, Linn M, Wheeldon E, Gand L, Birnboeck H, Hoffmann G (2004) Antitumor activity of erlotinib (OSI-774, Tarceva) alone or in combination in human non-small cell lung cancer tumor xenograft models. Anticancer Drugs 15(5):503–512.  https://doi.org/10.1097/01.cad.0000127664.66472.60 CrossRefPubMedGoogle Scholar
  57. 57.
    Herbst RS, Giaccone G, Schiller JH, Natale RB, Miller V, Manegold C, Scagliotti G, Rosell R, Oliff I, Reeves JA, Wolf MK, Krebs AD, Averbuch SD, Ochs JS, Grous J, Fandi A, Johnson DH (2004) Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial–INTACT 2. J Clin Oncol 22(5):785–794.  https://doi.org/10.1200/JCO.2004.07.215 CrossRefPubMedGoogle Scholar
  58. 58.
    Giaccone G, Herbst RS, Manegold C, Scagliotti G, Rosell R, Miller V, Natale RB, Schiller JH, Von Pawel J, Pluzanska A, Gatzemeier U, Grous J, Ochs JS, Averbuch SD, Wolf MK, Rennie P, Fandi A, Johnson DH (2004) Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial–INTACT 1. J Clin Oncol 22(5):777–784.  https://doi.org/10.1200/JCO.2004.08.001 CrossRefPubMedGoogle Scholar
  59. 59.
    Herbst RS, Prager D, Hermann R, Fehrenbacher L, Johnson BE, Sandler A, Kris MG, Tran HT, Klein P, Li X, Ramies D, Johnson DH, Miller VA, Group TI (2005) TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 23(25):5892–5899.  https://doi.org/10.1200/JCO.2005.02.840 CrossRefPubMedGoogle Scholar
  60. 60.
    Cheng Y, Murakami H, Yang PC, He J, Nakagawa K, Kang JH, Kim JH, Wang X, Enatsu S, Puri T, Orlando M, Yang JC (2016) Randomized phase II trial of gefitinib with and without pemetrexed as first-line therapy in patients with advanced nonsquamous non-small-cell lung cancer with activating epidermal growth factor receptor mutations. J Clin Oncol 34(27):3258–3266.  https://doi.org/10.1200/JCO.2016.66.9218 CrossRefPubMedGoogle Scholar
  61. 61.
    Wu YL, Lee JS, Thongprasert S, Yu CJ, Zhang L, Ladrera G, Srimuninnimit V, Sriuranpong V, Sandoval-Tan J, Zhu Y, Liao M, Zhou C, Pan H, Lee V, Chen YM, Sun Y, Margono B, Fuerte F, Chang GC, Seetalarom K, Wang J, Cheng A, Syahruddin E, Qian X, Ho J, Kurnianda J, Liu HE, Jin K, Truman M, Bara I, Mok T (2013) Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial. Lancet Oncol 14(8):777–786.  https://doi.org/10.1016/s1470-2045(13)70254-7 CrossRefPubMedGoogle Scholar
  62. 62.
    Han B, Jin B, Chu T, Niu Y, Dong Y, Xu J, Gu A, Zhong H, Wang H, Zhang X, Shi C, Zhang Y, Zhang W, Lou Y, Zhu L, Pei J (2017) Combination of chemotherapy and gefitinib as first-line treatment for patients with advanced lung adenocarcinoma and sensitive EGFR mutations: a randomized controlled trial. Int J Cancer 141(6):1249–1256.  https://doi.org/10.1002/ijc.30806 CrossRefPubMedGoogle Scholar
  63. 63.
    Janne PA, Wang X, Socinski MA, Crawford J, Stinchcombe TE, Gu L, Capelletti M, Edelman MJ, Villalona-Calero MA, Kratzke R, Vokes EE, Miller VA (2012) Randomized phase II trial of erlotinib alone or with carboplatin and paclitaxel in patients who were never or light former smokers with advanced lung adenocarcinoma: CALGB 30406 trial. J Clin Oncol 30(17):2063–2069.  https://doi.org/10.1200/jco.2011.40.1315 CrossRefPubMedPubMedCentralGoogle Scholar
  64. 64.
    Sugawara S, Oizumi S, Minato K, Harada T, Inoue A, Fujita Y, Maemondo M, Yoshizawa H, Ito K, Gemma A, Nishitsuji M, Harada M, Isobe H, Kinoshita I, Morita S, Kobayashi K, Hagiwara K, Kurihara M, Nukiwa T (2015) Randomized phase II study of concurrent versus sequential alternating gefitinib and chemotherapy in previously untreated non-small cell lung cancer with sensitive EGFR mutations: NEJ005/TCOG0902. Ann Oncol 26(5):888–894.  https://doi.org/10.1093/annonc/mdv063 CrossRefPubMedGoogle Scholar
  65. 65.
    Yoshimura N, Kudoh S, Mitsuoka S, Yoshimoto N, Oka T, Nakai T, Suzumira T, Matusura K, Tochino Y, Asai K, Kimura T, Kawaguchi T, Hirata K (2015) Phase II study of a combination regimen of gefitinib and pemetrexed as first-line treatment in patients with advanced non-small cell lung cancer harboring a sensitive EGFR mutation. Lung Cancer 90(1):65–70.  https://doi.org/10.1016/j.lungcan.2015.06.002 CrossRefPubMedGoogle Scholar
  66. 66.
    Kanda S, Horinouchi H, Fujiwara Y, Nokihara H, Yamamoto N, Sekine I, Kunitoh H, Kubota K, Tamura T, Ohe Y (2015) Cytotoxic chemotherapy may overcome the development of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) therapy. Lung Cancer 89(3):287–293.  https://doi.org/10.1016/j.lungcan.2015.06.016 CrossRefPubMedGoogle Scholar
  67. 67.
    Hirsch FR, Kabbinavar F, Eisen T, Martins R, Schnell FM, Dziadziuszko R, Richardson K, Richardson F, Wacker B, Sternberg DW, Rusk J, Franklin WA, Varella-Garcia M, Bunn PA Jr, Camidge DR (2011) A randomized, phase II, biomarker-selected study comparing erlotinib to erlotinib intercalated with chemotherapy in first-line therapy for advanced non-small-cell lung cancer. J Clin Oncol 29(26):3567–3573.  https://doi.org/10.1200/JCO.2010.34.4929 CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of OncologyJinan Central Hospital Affiliated to Shandong UniversityJinanPeople’s Republic of China

Personalised recommendations